Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Brussels, Belgium. 21st December 2020. Exterior view of Pfizer Pharmaceutical company's offices.

Mergers & acquisitions

Pfizer Wins Metsera Bidding War Over Novo With Final $10B Price Tag

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drugmaker, Metsera sided with its original suitor in a final agreement announced late Friday evening.

November 7, 2025

1 min read

Dan Samorodnitsky

North view of the White House, with waving flag and cloudy sky, on a reflective surface that could be glass or water. 3D Illustration

Mergers & acquisitions

Novo CEO Fires Back at Pfizer From White House: ‘Put Your Hand in Your Pocket’

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ongoing bidding war between Novo Nordisk and Pfizer over obesity biotech Metsera.

November 7, 2025

2 min read

Annalee Armstrong

Vaccine concept. Conspiracy theory. Young woman against vaccination. Vector illustration in a flat style

Vaccines

Pesky ‘Macro Factors’—aka RFK Jr.—Come for Vaccine Pharmas’ Wallets

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all suffering revenue hits to their vaccine programs.

November 7, 2025

4 min read

Annalee Armstrong

Goal concept. Human hand in dotted pop art style pointing on the target for red paper plane. Vector illustration

IgA nephropathy

Vera Builds ‘Compelling Profile’ for Atacicept in IgAN, Eyes Q4 Filing

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market.

November 7, 2025

2 min read

Tristan Manalac

The headquarters of Intellia Therapeutics, a brick building with two triangular shapes in its roof

Gene therapy

Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex-z.

November 7, 2025

2 min read

Tristan Manalac

Oct 9, 2019 Milpitas / CA / USA - Johnson & Johnson Vision offices in Silicon Valley; Johnson & Johnson Vision Care, Inc. is part of the American multinational corporation Johnson&Johnson

Approvals

J&J Wins Expansion for Top-Selling Cancer Drug in First for Smoldering Multiple Myeloma

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of progression to active disease.

November 7, 2025

2 min read

Tristan Manalac

Vector of a young man rejects drugs when being offered

Opinion

The GLP-1 Paradox—Why Is a $95B Obesity Market Ignoring Its Biggest Problem?

The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall obesity market unless we approach the problem head on.

November 7, 2025

5 min read

James O’Mara

Buying tickets. The hands of the person holding the tickets. Isolated illustration on a yellow background. Template for the design. Trending vector graphics.

Regulatory

Wegovy, Casgevy Among Latest FDA Priority Review Voucher Recipients

The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, with the exception of Eli Lilly’s orforglipron, the vouchers are for drugs that are already on the market.

November 6, 2025

3 min read

Dan Samorodnitsky